Success Story: NAILG Helps Researcher Turn Biotechnology Innovation into NIW Approval in Just Over 2 Months
Client’s Testimonial:
"Thank you again for all your help throughout this journey.”
On August 18th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Scientist in the Field of Biotechnologies (Approval Notice).
General Field: Biotechnologies
Position at the Time of Case Filing: Postdoctoral Research Scientist
Country of Origin: South Korea
State of Residence at the Time of Filing: New York
Approval Notice Date: August 18th, 2026
Processing Time: 2 months, 3 days (Premium Processing Requested)
Case Summary:
For this NIW petition, we presented the client’s research as a progression toward a new generation of programmable biological technologies. The client’s work combines synthetic biology and computational approaches to engineer biological systems that can improve therapies for cancer and immune-related diseases. These efforts are intended to make biological therapies more precise, controllable, and effective.
The client had already established a strong foundation for pursuing these objectives. With a Ph.D. in biomedical engineering, he had authored 7 peer-reviewed journal articles, as well as 1 preprint. His published work had accumulated 1,019 citations, and several individual papers demonstrated particularly strong citation performance relative to other publications from the same years and fields. Specifically, 3 papers ranked among the top 0.1% most cited articles for their respective publication years. The client had also completed at least 7 peer reviews, providing another indication that his expertise was recognized within the biotechnology research community.
North America Immigration Law Group (Chen Immigration Law Associates) further demonstrated the significance behind these credentials by showing how other scientists had built upon the client’s research. His work on bacterial systems for cancer immunotherapy had informed subsequent research involving personalized cancer treatment, approaches for improving the targeting of solid tumors, and new methods for controlling bacterial delivery to tumor sites. We used these examples of independent reliance to show how his findings had become useful to researchers developing their own therapeutic technologies.
The petition also placed the client’s research within its broader U.S. context. The client's work had received funding from the National Institutes of Health (NIH) and addressed challenges associated with cancer treatment, including the need for therapies capable of targeting tumors more precisely while reducing unwanted systemic effects. We also explained how the client's expertise in synthetic biology, computational biology, predictive modeling, and biomanufacturing intersected with areas identified as critical and emerging technologies. This evidence helped connect the client’s specialized research record with wider U.S. interests in biotechnology, health innovation, and cancer treatment.
The favorable result reflects the client’s substantial record of influential biotechnology research together with NAILG’s careful presentation of how his past achievements, independent research impact, and future plans supported the NIW requirements. We are glad to have assisted the client in reaching this important milestone as he continues developing programmable biological technologies with potential applications in more precise and effective cancer therapies.